Sugi Predict

Sugi Predict / Compounds / SCHEMBL9019941

SCHEMBL9019941

SCHEMBL9019941

COC(=O)C(O)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ LTA4H P09960 2/20 0.57
▸ MAOB P27338 3/20 0.55
▸ MEN1 O00255 1/20 0.54
▸ ALOX5 P09917 1/20 0.54
▸ NR4A2 P43354 1/20 0.54
▸ SMPD1 P17405 1/20 0.52
▸ EPOR P19235 1/20 0.52
▸ BCHE P06276 1/20 0.51
▸ PTPN1 P18031 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ SGMS2 Q8NHU3 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9432429 1.00 KMT2A (0.59) KMT2ASMN1; SMN2LTA4HMAOBMEN1
SCHEMBL2853880 0.86 ALOX5 (0.63) KMT2ASMN1; SMN2LTA4HMAOBMEN1
SCHEMBL5494784 0.86 KMT2A (0.64) KMT2ASMN1; SMN2MAOBMEN1ALOX5
SCHEMBL25311665 0.85 KMT2A (0.57) KMT2ASMN1; SMN2LTA4HMAOBMEN1
SCHEMBL3609023 0.85 KMT2A (0.64) KMT2ASMN1; SMN2LTA4HMAOBMEN1
SCHEMBL31070956 0.85 KMT2A (0.57) KMT2ASMN1; SMN2LTA4HMAOBMEN1
SCHEMBL5360486 0.85 KMT2A (0.54) KMT2ASMN1; SMN2LTA4HMAOBMEN1
SCHEMBL10603321 0.85 LTA4H (0.62) SMN1; SMN2LTA4HMAOBALOX5NR4A2
SCHEMBL7444074 0.85 LTA4H (0.62) SMN1; SMN2LTA4HMAOBALOX5NR4A2
SCHEMBL22939109 0.83 KMT2A (0.51) KMT2ASMN1; SMN2LTA4HMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023137634-A1 TRICYCLIC COMPOUND, PREPARATION THEREFOR, PHARMACEUTICAL COMPOSITION AND USE 上海奕拓医药科技有限责任公司 2023-07-27 — — WO disclosed
WO-2023137634-A1 TRICYCLIC COMPOUND, PREPARATION THEREFOR, PHARMACEUTICAL COMPOSITION AND USE 上海奕拓医药科技有限责任公司 2023-07-27 — — WO disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 — — US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 — — US disclosed
WO-2008073623-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-06-19 — — WO disclosed
EP-0422597-B1 Derivatives of phenylacetic acid and fungicides containing them BASF AG (DE) 1996-07-24 — — EP disclosed
US-5286750-A For crops or ornamental plants BASF AKTIENGESELLSCHAFT (DE) 1994-02-15 — — US disclosed
EP-0422597-A2 Derivatives of phenylacetic acid and fungicides containing them BASF Aktiengesellschaft (DE) 1991-04-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 KMT2A 2022/4885SMN1; SMN2 4561/4885LTA4H 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.